leadf
logo-loader
viewe-Therapeutics PLC

e-Therapeutics launches second phase I anti-cancer drug trial

drug_research_350_50502f1b06d36.jpg

Drug discovery and development company e-Therapeutics (LON:ETX) revealed it has started a second phase I clinical trial of its anti-cancer drug ETS2101.

It comes after an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California in June.

“The initiation of a second trial with ETS2101 reflects the growing momentum in our clinical development programme,” said e-Therapeutics chief executive Professor Malcolm Young.

“We hope that the promising preclinical data supporting this drug will ultimately translate into benefits for patients and look forward to seeing the first findings from cancer trials later this year.”

The company said up to 45 patients with a variety of solid tumours will take part in the trial, which is to take place at St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

Like the brain cancer study, the UK trial has a dose-escalating design, which means groups of patients will receive successively higher doses of the ETS2101.

While the primary objectives are to test the safety of the drug and pick out an appropriate dose for phase II development, secondary objectives include assessing the drug’s activity and how it spreads in the body.

Quick facts: e-Therapeutics PLC

Price: 14.75 GBX

AIM:ETX
Market: AIM
Market Cap: £61.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read